Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sex Hormones and Pericardial Adipose Tissue

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03035526
Recruitment Status : Completed
First Posted : January 30, 2017
Last Update Posted : January 30, 2017
Sponsor:
Information provided by (Responsible Party):
Aydogan Aydogdu, Gulhane School of Medicine

Brief Summary:
In this study, our aim is to show the relation between sex hormones and PAT and to confirm whether PAT is associated with coronary artery calcification (CAC) in different testosterone levels in the males.

Condition or disease
Pericardial Adipose Tissue and Sex Hormones

Layout table for study information
Study Type : Observational
Actual Enrollment : 3213 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Do Endogenous Sex Hormones Affect Pericardial Adipose Tissue Volume of Males in The Multi-Ethnic Study of Atherosclerosis (MESA)?
Actual Study Start Date : January 2000
Actual Primary Completion Date : January 2002
Actual Study Completion Date : January 2002

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hormones

Group/Cohort
3161 men (45-84 years old)
3161 men without known coronary artery disease



Primary Outcome Measures :
  1. Relation ship between pericardial adipose tissue and sex hormones in males [ Time Frame: years ]
    Total testosterone and sex hormone binding globulin levels were related with pericardial adipose tissue



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years to 84 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
3161 men (45-84 years old; white, black, Hispanic, or Chinese) at 6 centers in the United States
Criteria

Inclusion Criteria:

  • 3213 males
  • African American
  • Caucasian
  • Asian (largely Chinese) and Hispanic adults aged 45-84 years and free of known cardiovascular disease at baseline (2000-2002)

Exclusion Criteria:

  • Patients with known coronary artery disease

Layout table for additonal information
Responsible Party: Aydogan Aydogdu, MD, Gulhane School of Medicine
ClinicalTrials.gov Identifier: NCT03035526     History of Changes
Other Study ID Numbers: AA1972
First Posted: January 30, 2017    Key Record Dates
Last Update Posted: January 30, 2017
Last Verified: January 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs